This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Recent Advances in the Assessment of Depression

Recent Advances in the Assessment of Depression



Time to Complete

30 minutes


February 8, 2016


January 15, 2017
Add to Queue

Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM
0.50 / CE for Pharmacists (0.05 CEUs)

Accredited Provider

This educational initiative is provided by CME Outfitters.

Commercial Supporter

This educational activity is supported by an educational grant from Allergan, Inc.

Program Description

Major depressive disorder (MDD) is a common condition with a high rate of recurrence, chronicity, staggering economic burden, and the highest estimates of disability in people of working age.1 The disability and disease burden is often attributable to the fact that a significant portion of patients with MDD will not achieve remission with initial treatment.2 Despite these challenges, MDD can be effectively managed, particularly when the clinician and patient mutually define what remission means to the patient and work together towards achieving sustained remission. Recent advances in psychopharmacotherapy have given patients with MDD new hope and clinicians new options. Novel and emerging therapies have demonstrated improved remission with new receptor targets, adjunctive therapies, and new approaches to treatment. The goal for the treatment of MDD is sustained symptom remission with total functional recovery.

This neuroscienceCME Snack on MDD featuring expert faculty offers new perspectives on treating this pervasive disorder and highlights residual symptoms as a challenge to clinicians.


1. Centers for Disease Control and Prevention [CDC]. Mental health basics. CDC Website. Updated July 2013. Accessed December 21, 2015.
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer -term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.PMID: 17074942.

Intended Audience

Physicians, pharmacists, and other health care professionals with an interest in mood disorders

Educational Objectives

At the end of this CME/CE activity, participants should be able to:

  • Engage the patient to develop a treatment strategy that addresses the cognitive and residual symptoms of depression
  • Routinely administer symptom assessment tools with patients with MDD to monitor clinical change over time
  • Initiate a treatment plan that includes the latest pharmacotherapeutic options for the treatment of MDD

Conflict Of Interest Disclosure Policy

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.


Alan F. Schatzberg, MD
Kenneth T. Norris, Jr. Professor
Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, CA

Dr. Schatzberg has disclosed that he received grants/research support from the Pritzker Foundation. He serves as a consultant to Lundbeck/Takeda Pharmaceuticals U.S.A., Inc.; Myriad Genetics, Inc.; Naurex Inc.; Neuronetics Inc.; One Carbon; and Pfizer Inc. He is a stockholder in Amnestix, Inc.; Cervel Neurotech, Inc.; Corcept Therapeutics; Merck & Co., Inc.; Pfizer Inc.; Titan Pharmaceuticals, Inc.; and Xhale, Inc. Other financial interests include American Psychiatric Association (Royalties) and Stanford University (Royalties).

Charles B. Nemeroff, MD, PhD
Leonard M. Miller Professor and Chairman
Director, Center on Aging
Department of Psychiatry and Behavioral Sciences
Leonard M. Miller School of Medicine
University of Miami
Miami, FL

Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Bracket (Clintara); Gerson Lehrman Group, Inc. (GLG) Healthcare & Biomedical Council; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Total Pain Solutions (TPS); and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara);Brain & Behavior Research Foundation (BBRF) (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]); Clintara; RiverMend Health, LLC; Skyland Trail; and Xhale, Inc. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); and GratitudeAmerica, Inc. He is a stockholder of AbbVie Inc,; Bracket (Clintara); Celgene Corporation; COPKO Health, Inc.; Seattle Genetics, Inc.; Titan Pharmaceuticals, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; Bracket (Clintara); CME Outfitters, LLC; Takeda Pharmaceuticals North America, Inc.; Xhale, Inc. Dr. Nemeroff has patients for method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).

Accredited Provider Disclosure

The CME Outfitters, LLC staff has nothing to disclose.

Planners' and Managers' Disclosures

Tony Graham, MD (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

CME Outfitters designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.




CE for Pharmacists

Accreditation Statement

CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.50 contact hours (0.05 CEUs)

Universal Activity Number: 0376-0000-16-013-H01-P

Activity Type: knowledge-based

Disclosure of Unlabeled Use

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, and Allergan, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


There are no fees for participating in this CME/CE activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.

To obtain a certificate, participants must receive a score of 75% or better on the post-test. The post-test can be accessed at the end of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact

If you have any other questions relating to your certificate or other issues with this activity, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue